524602 BANDARAM

Bandaram Pharma Packtech Share Price

 

 

Start SIP in BANDARAM

Start SIP

Performance

  • Low
  • ₹33
  • High
  • ₹33
  • 52 Week Low
  • ₹23
  • 52 Week High
  • ₹52
  • Open Price₹33
  • Previous Close₹35
  • Volume931

Investment Returns

  • Over 1 Month + 23.52%
  • Over 3 Month -9.38%
  • Over 6 Month -13.06%
  • Over 1 Year -27.77%

Smart Investing Starts Here Start SIP with Bandaram Pharma Packtech for Steady Growth!

Invest Now

Bandaram Pharma Packtech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 313.3
  • PEG Ratio
  • -3.6
  • Market Cap Cr
  • 59
  • P/B Ratio
  • Average True Range
  • 3.22
  • EPS
  • -
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 2.15
  • RSI
  • 51.73
  • MFI
  • 78.04

Bandaram Pharma Packtech Financials

Bandaram Pharma Packtech Technicals

EMA & SMA

Current Price
₹33.03
-1.73 (-4.98%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹32.95
  • 50 Day
  • ₹31.26
  • 100 Day
  • ₹32.65
  • 200 Day
  • ₹35.14

Resistance and Support

33.03 Pivot Speed
  • R3 33.03
  • R2 33.03
  • R1 33.03
  • S1 33.03
  • S2 33.03
  • S3 33.03

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Bandaram Pharma Packtech has an operating revenue of Rs. 40.32 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 4% needs improvement, ROE of 4% is fair but needs improvement. The stock from a technical standpoint is trading below to its 200DMA and around 17% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 37 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 23 indicates it belongs to a strong industry group of Finance-Blank Check and a Master Score of E is the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bandaram Pharma Packtech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results
2025-06-20 Preferential Issue of shares & Others Inter alia, to consider 1. Acquisition of Company/ies for consideration in cash or other than cash, by way of Private Placement of equity shares or such other security. 2. Other business.matters. issue of equity shares of Rs. 10/- in the ratio of 3:1 @ par.
2025-05-30 Audited Results
2025-02-14 Quarterly Results
Date Purpose Remarks
2025-09-22 FINAL Rs.0.10 per share(1%)Final Dividend
View Bandaram Pharma Packtech Dividend History Arrow

Bandaram Pharma Packtech F&O

Bandaram Pharma Packtech Shareholding Pattern

62.62%
0%
36.52%
0.86%

About Bandaram Pharma Packtech

  • NSE Symbol
  • BANDARAM
  • BSE Symbol
  • 524602
  • Chairman & Managing Director
  • Mr. B Deepak Reddy
  • ISIN
  • INE875N01036

Similar Stocks to Bandaram Pharma Packtech

Bandaram Pharma Packtech FAQs

Bandaram Pharma Packtech share price is ₹33 As on 09 December, 2025 | 04:44

The Market Cap of Bandaram Pharma Packtech is ₹59.4 Cr As on 09 December, 2025 | 04:44

The P/E ratio of Bandaram Pharma Packtech is 313.3 As on 09 December, 2025 | 04:44

The PB ratio of Bandaram Pharma Packtech is 3.2 As on 09 December, 2025 | 04:44

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23